Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

← catalyst calendar

NCT05678673 · readout in 118 d

Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

317actual

Sites

163

Countries

Argentina, Australia, Brazil +22

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-01-01

actual

When the study began enrolling

Primary completion

2026-12-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-06-30

estimated

The whole study's end, after follow-up

First posted

2023-01-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-Clear Cell Renal Cell Carcinoma

Interventions

Drug: XL092
Drug: Nivolumab — also filed as Opdivo®
Drug: Sunitinib Malate — also filed as Sutent®

Primary outcomes

what the primary-completion date above is the date OF

Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)

measured Approximately 27 months after the first subject is randomized

Objective response rate (ORR) as assessed by BIRC per RECIST 1.1

measured Up to 24 months after the first subject is randomized

Publications

PMID 40008409 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed